GREENPEAK Partners: CERTANIA GRUPPE takes over Alphalytik
Berlin/ Munich — Alphalytik Pharmaservice GmbH, a leading expert in pharmaceutical analytics, announces its integration into GREENPEAK Partners’ subsidiary, the CERTANIA Group, a dynamic group specializing in testing, inspection and certification services.
This strategic move represents a significant milestone for Alphalytik as it expands its offering of specialized stability testing and method validation services to a broader range of pharmaceutical clients. Alphalytik was founded in 1995 and is headquartered in Berlin, Germany.
Alphalytik has built a strong reputation as an independent laboratory specializing in drug product stability testing, method development and release testing under Good Manufacturing Practice (GMP) and US Food and Drug Administration (FDA) guidelines.
With a focus on complex drug formulations, including low-dose and hormonal preparations, Alphalytik serves a diverse customer base that includes some of the world’s leading pharmaceutical companies.
The company’s expertise in ensuring the long-term safety and efficacy of pharmaceutical products makes it a reliable partner.
The merger with CERTANIA will give Alphalytik access to a powerful platform that will enable it to expand its service offering and strengthen its position in the pharmaceutical analytics market.
This partnership will enable Alphalytik to meet the growing demand for specialized pharmaceutical testing services driven by increasing drug development and regulatory requirements.
Dr. Nicolas Schauer has been appointed as the new Managing Director, while Dr. Richard Herzog, the founder of Alphalytik, will continue to support the company in an advisory capacity to ensure a seamless transition and continuity in customer relationships.
“We are excited to join CERTANIA, a group that shares our commitment to excellence in pharmaceutical testing,” said Dr. Richard Herzog, founder of Alphalytik.
“This partnership will provide us with the resources and support we need to continue providing high-quality, reliable services to our customers while pursuing new growth opportunities.” Karsten Xander, CEO and founder of CERTANIA, welcomed Alphalytik to the group and emphasized the strategic importance of the acquisition.
“The addition of Alphalytik significantly strengthens CERTANIA’s position in the field of pharmaceutical laboratory analytics. Their expertise in stability testing and method validation complements our existing services and we see great potential for synergies and growth.”
The acquisition of Alphalytik by CERTANIA underlines the Group’s commitment to expanding its competencies in the life sciences and strengthening its market presence in Germany and beyond.
The integration is expected to drive innovation, enhance the service offering and promote significant growth within the CERTANIA Group. CERTANIA offers medium-sized, knowledge-based companies a platform to develop under one roof, retain entrepreneurial freedom and at the same time benefit from the resources and support of the group. About Alphalytik: Founded in 1995 and headquartered in Berlin, Alphalytik Pharmaservice GmbH is a specialized pharmaceutical laboratory offering stability testing, method development and release testing for medicinal products.
With a focus on complex analytical requirements, Alphalytik serves a diverse clientele, including leading pharmaceutical companies.
The company’s expertise and accredited services ensure the long-term safety and efficacy of pharmaceutical products.
For more information, visit alphalytik.com. About CERTANIA: Under the umbrella of CERTANIA Holding GmbH, a new global market player in the fields of Testing, Inspection & Certification is emerging.
The group offers medium-sized partners a sustainable home for their life’s work.
CERTANIA enables entrepreneurs and owners to develop their business with like-minded people while preserving their entrepreneurial roots, corporate culture, brand and values.
More information at certania.com